Jeffrey L. Anderson, MD
Disclosures: Advisor-Johnson & Johnson (Relationship has ended)|Grant or research support-Novartis AG|Grant or research support-Milestone|Grant or research support-SomaLogic - 04/05/2022
OMB No. 0925-0001/0002 (Rev. 08/12), Biographical Sketch Format Page

Program Director/Principal Investigator (Last, First, Middle):             


Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.



Jeffrey L Anderson


Professor (Internal Medicine) with Tenure, Univ. of Utah; Distinguished Research Physician and immediate past Vice Chair for Research, IMC

eRA COMMONS USER NAME (credential, e.g., agency login)



EDUCATION/TRAINING  (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)



(if applicable)



University of Utah, Salt Lake City, UT




Harvard Medical School, Boston, MA




Massachusetts, General Hospital, Boston, MA



Internal Med. Resident

National Institutes of Health, Bethesda, MD



Staff Assoc., NIAMDD

Stanford University School of Medicine, CA



Cardiology Fellow


  1. Personal Statement.

I have been continuously involved in clinical cardiovascular research for over 40 years in academic medicine as an investigator and principal investigator and also as an FDA advisor, as a pharmaceutical research director, and as a clinical trials’ data monitoring committee member and chair. This work has resulted in 780 peer-reviewed and invited publications and 691 abstracts. Much of my research and publications in recent years specifically relates to the elucidation of environmental, metabolic, and genetic risk factors for cardiovascular (CV) diseases and to intervention trials for CV disease prevention and treatment. This experience, together with my training in electrophysiology and arrhythmias (FHRS), place me in an excellent position to collaborate on this exciting project.

  1. Anderson JL, Martin RG, Chang C, Mora PT, Livingston DM. Nuclear preparations of SV40-transformed cells contain tumor-specific transplantation antigen activity. Virology 1977; 76:420-425
  2. Anderson JL, Horne BD, Camp NJ, Muhlestein JB, Hopkins PN, Cannon-Albright LA, Mower CP, Park JJ, Clarke JL, Nicholas ZP, McKinney JT, Carlquist JF. Joint effects of common genetic variants from multiple genes and pathways on the risk of premature coronary artery disease. Am Heart J 2010; 160:250-6
  3. Anderson JL, Horne BD, Stevens SM, Woller SC, Samuelson KM, Mansfield JW, Robinson M, Barton S, Brunisholz K, Mower CP, Huntinghouse JA, Rollo JS, Siler D, Bair TL, Knight S, Muhlestein JB, Carlquist JF. (2012) A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 2012. Apr 24;125(16):1997-2005 .
  4.       Anderson JL, May HT, Knight S, Bair TL, Le VT, Muhlestein JB, Knowlton KU, Horne BD. Association of Sociodemographic Factors and Blood Group Type With Risk of COVID-19 Infection in a US Population. JAMA Netw Open 2021; in press.

B. Positions and Honors

Professional Experience

Staff Associate, NIH/NIAMDD, 1974-76

Assistant Professor of Medicine, University of Michigan, 1978-80

Director, Coronary Care, LDS Hospital, 1980-89

Assistant Professor of Medicine, University of Utah, 1980-82

Associate Professor of Medicine, University of Utah, 1982-89

Professor of Medicine with Tenure, University of Utah, 1989-1998; 1999-

Chief, Division of Cardiology, LDS Hospital, 1984-97

Chief of Cardiology, University of Utah, 1999-2001

Associate Chief of Cardiology, LDS Hospital & Intermountain Medical Center, 2002-15

Vice-Chair for Research, Intermountain Medical Center, 2008-15


Other Experience and Professional Memberships

Diplomat: Internal Medicine, ABIM (1975) Cardiovascular Subspecialty (1979), Cardiac Electrophysiology Subspecialty (1992, 2002, 2012), all current

Governor, Utah Chapter, American College of Cardiology, 1984-88

President, Utah Affiliate, American Heart Association, 1986-87; 2002-03

Member and Chair, FDA Cardiorenal Advisory Committee, 1992-96

Executive Director, Cardiovascular Clinical Research, Merck Research Laboratories, 1997-99

President, American Heart Association, Western States Affiliate, 2008-2010

Vice-Chair / Chair, Task Force on Practice Guidelines, ACC/AHA, 2009-2015

Fellow, American Heart Association, 1982-

Fellow, American College of Cardiology, 1980-

Fellow/Master, American College of Physicians, 1982, 2002-

Fellow, Heart Rhythm Association, 2012-

Member, Association of University Cardiologists, 1996-

Member, Association of Professors of Cardiology, 1999-2002

Editorial Board Member, Am J Cardiol (1987- ); J Am Coll Cardiol,(1992-96; 2000-2005)


Honors and Awards

National Merit Scholar Awardee, 1962

Pi Beta Kappa, University of Utah, 1968

Valedictorian, University of Utah, 1968

Magna Cum Laude (BA, Chemistry), University of Utah, 1968

Bonner Award for Top Chemistry Graduate, University of Utah, 1968

Cum Laude Graduate, Harvard Medical School, 1972

Golden Apple Award, best Teaching Attending Physician, LDS Hospital Housestaff, 1988

Researcher of the Year Award, Intermountain Health Care, 1994

Best Heart Doctors in America” recognition. Good Housekeeping, March, 1996 (1 of 94 Cardiologists)

Honorary Professor of Medicine, Xi’an Medical University, Xi’an, China, 1997

Christi U. Smith Endowed Chair in Cardiology Research, University of Utah, 2000-2002

Laureate Award (2000) and Master (2002), American College of Physicians.

Heart of Gold Award, Utah Division, American Heart Association, 2004

Gold Caduceus Award, Deseret Research Foundation, Intermountain Healthcare, 2006

Physician Volunteer of Year, Western States Affiliate, AHA, 2013

Legacy of Life Award (outstanding career research award), Intermountain Healthcare, Intermountain Research and Medical Foundation’s Heart and Lung Institute, 2015.


C. Contributions to Science

1. After medical residency, I spent 2 years at NIH as staff associate working in the laboratory of cellular and molecular biology, where my cell-culture work identified the T-antigen of the SV40 virus (which contaminated early polio vaccines) as the transforming factor (2,3 above). During fellowship, which involved cardiac transplantation research at Stanford, I published with colleagues on the malignancy potential of immunosuppressive therapy (a). Later, in academic cardiology at Utah, I was PI of the first randomized study of reperfusion therapy (with thrombolytics) to show its benefit in ST-elevation MI, now a standard of therapy (b). In heart failure, I published the first randomized trial of beta-blockers (c), now also a standard of care. And I was referring cardiologist for the first total artificial heart patient and wrote the report for the NEJM (d). In the field of arrhythmia, I was involved with the initial clinical development of the potent antiarrhythmic flecainide (e), and later showed its potential for harm after MI in the seminal CAST study (f), but (subsequently) its safety and utility for AF without structural heart disease.

a.                  Krikorian JG, Anderson JL, Bieber CP, Penn I, Stinson EB. The development of malignancy following cardiac transplantation. JAMA 1978; 240: 639-643

b.                  Anderson JL, Marshall HW, Bray BE, Lutz JR, Frederick PR, Yanowitz FG, Datz FL, Klausner SC, Hagan AD. A randomized trial of intracoronary streptokinase in the treatment of acute myocardial infarction. N Engl J Med 1983; 308:1312-1318

c.                   Anderson JL, Lutz JR, Gilbert EM, Sorensen SG, Yanowitz FG, Menlove RL, Bartholomew MB. A randomized trial of low-dose beta-blockade for idiopathic-dilated cardiomyopathy. Am J Cardiol 1985; 55:471-475

d.                  DeVries WC, Anderson JL, Joyce LD, Anderson F, Hammond EH, Jarvik RK, Kolff WJ. Clinical use of the artificial heart. N Engl J Med 1983; 310: 373-378

e.                  Anderson JL, Stewart JR, Perry BA, Van Hamersveld DD, Johnson TA, Conard GJ, Chang SF, Kvam DC, Pitt B. Oral flecainide acetate for treatment of ventricular arrhythmias in man. N Engl J Med 1981; 305:474-477

f.                    The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Effect of encainide or flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321:406-412200.             

2. In my mid-career, in the 1990’s and early 2000’s, my colleagues and I turned our primary interest from acute interventions to prevention and to cardiovascular risk factors. Specifically, we became interested in the impact of newly discovered genetic polymorphisms on cardiovascular disease risk. To assist with this, we began (1993) to draw blood samples for plasma and DNA among consenting patients undergoing coronary angiography. This has resulted in a unique biobank, linked to clinical information and follow-up outcomes, which has now grown to over 30,000 samples. However, it became clear from early genetic studies, most using the bank, that in many cases initial reports of associations often could not be replicated, and, where confirmed, they had small effect sizes (2a). Thus, we became interested in combining several of these polymorphisms to generate a “genetic risk score”. The paper 2b was the first in the literature to use the term “genetic risk score”. This approach was further developed with support from an NIH (R01) study, resulting in several subsequent manuscripts. Parallel interest in genetic applications to clinical medicine was pursued in the form of pharmacogenetic-guided therapy of warfarin (2c), leading to a first randomized clinical trial and later participation in the critical NIH-multicenter study: COAG (2d).

a. Horne BD, Carlquist JF, Muhlestein JB, Bair TL, Anderson JL. Association of variation in the chromosome 9p21 locus with myocardial infarction versus chronic coronary artery disease. Circulation Cardiovascular Genetics 2008; 1:85-92 (PMID: 19956784)

b. Horne BD, Anderson JL, Carlquist JF, Muhlestein JB, Renlund DG, Bair TL, Pearson RR, Camp NJ. Generating genetic risk scores from intermediate phenotypes for use in association studies of clinically significant endpoints. Ann Human Genetics. 2005; 69:176-186. (PMID 15720299)

c. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SFS, May HT, Samuelson KM, Muhlestein JB, Carlquist JF. A randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007; 116:2563-2570. (PMID: 17989110)

d. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, et-al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013: 369:2283-93 (PMID: 24251361)

3. Our group’s experience with genetic risk in recent years has been accompanied by a parallel interest in discovering and validating non-genetic markers of risk and integrating them into non-genetic risk prediction models and risk scores. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, Hall S, Brady J, Egger M, Horne B, Lim T. Controlled Trial of Azithromycin in Patients with Coronary Artery Disease and Serologic Evidence for Chlamydia Pneumoniae Infection: the Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) Study. Circulation 1999; 99:1540-7 (PMID 10096928)

a.      Horne BD,  May HT, Muhlestein JB, Ronnow BS, Lappe DL, Renlund DG, Kfoury AG, Carlquist JF, Fisher PW, Pearson RR, Bair TL, Anderson JL. Exceptional mortality prediction by risk scores from common laboratory tests. Am J Med 2009; 122 (6):550-8 (PMID: 19488718)

b.      Horne BD, Anderson JL, Muhestein JB, Ridker PM, Paynter VP. The complete blood count risk score and its components including the RDW are associated with mortality in the JUPITER Trial. Eur J Prev Cardiol 2015; 22:519-526 (PMID: 24403296).

c.      Pope CA, Muhlestein JB, May HT, Renlund DG, Anderson JL, Horne BD. Ischemic heart disease events triggered by short-term exposure to fine particulate air pollution. Circulation 2006; 114:2443-2448 (PMID: 17101851)

OMB No. 0925-0001/0002 (Rev. 08/12 Approved Through 8/31/2015)              Page                   Biographical Sketch Format Page